Ending AIDS will not happen unless women have new options to use to keep themselves healthy and safe, International Partnership for Microbicides CEO Zeda F. Rosenberg and Microbicide Trials Network Principal Investigator Sharon Hillier argue in this exclusive commentary.

The views in this opinion piece do not necessarily reflect Devex's editorial views.

About the authors

  • Zeda Rosenberg

    Zeda Rosenberg is CEO of IPM, a nonprofit working to develop new HIV prevention and sexual and reproductive health products for women. Previously, she served as scientific director for the HIV Prevention Trials Network at Family Health International, and senior scientist at the U.S. National Institute of Allergy and Infectious Diseases at NIH. She received her master's in epidemiology and a doctorate in microbiology from Harvard University.
  • Sharon Hillier

    Dr. Sharon Hillier is professor and vice chair for faculty affairs, and director of reproductive infectious disease research in the department of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine. In addition, she is a senior investigator at the University of Pittsburgh-affiliated Magee-Womens Research Institute. As co-principal investigator of the Microbicide Trials Network funded by the U.S. National Institutes of Health, Hillier oversees an expansive portfolio of clinical trials focused on evaluating a range of HIV prevention products for different high-risk populations.